Surfing the MASH Tsunami
Driving the Discussion in Fatty Liver Disease. Join hepatology researcher and Key Opinion Leader Jörn Schattenberg, Liver Wellness Advocate Louise Campbell, and Forecasting and Pricing Guru Roger Green and a global group of Key Opinion Leaders and patient advocates as they discuss key issues in Fatty Liver disease, including epidemiology, drug development, clinical pathways, non-invasive testing, health economics and regulatory issues, from their own unique perspectives on the Surfing the MASH Tsunami podcast. #MASH #MAFLD #FattyLiver #livertwitter #AASLD #GlobalLiver #NoNASH #EASL
Surfing the MASH Tsunami
S5 - E7.5 - Will Increasing the Focus on MASH via Rezdiffra Overwhelm the Healthcare System?
Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.
This conversation asks what impact Rezdiffra patient education might have on a U.S. healthcare system in which 38% of American adults live with some form of MASLD and 15% live with MASH.
Louise Campbell starts off by saying she is “slightly fed up” with the idea that we cannot proceed too quickly for fear of overwhelming the system. Louise would rather flip focus to push systems to build the capacity they will need to handle the flow of patients that will certainly grow over time. Mike Betel agrees and discusses two Fatty Liver Alliance activities in Canada, one of which is a survey of 27,000 primary care physicians.
Roger Green pushes back slightly on Louise’s comment about overwhelming the system. He suggests that building capacity may be easier in countries with government-run healthcare systems, where one group can make and implement national decisions, than in the fragmented private US system where everything is measured in terms of short-term profit. Jeff McIntyre agrees with Louise’s point in that we can’t think in terms of “don’t burden the provider anymore.” He then discusses an innovarite solution the US Veterans Administration is implementing.
Louise points to the importance of systems solutions in view of her belief that most patient management in MASLD will fall to primary care within the next 5-7 years. This stresses the importance of systems enhancements and growing the population of advanced providers.